NEWAMSTERDAM PHARMA CO NV
NAMSNASDAQπ #1764 by market capUS Equity
$18.40βΌ $1.09 (β5.57%)
Market closed Β· at closeTrack NAMS
Get earnings, price moves & breaking news on Telegram
24hβΌ 5.6%
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$2.20B
Small Cap
πRevenue Growth (YoY)
-26.4%
Declining
πGross Margin
β
π΅FCF Margin
452.6%
Strong
βοΈP/S Ratio
85.1x
Expensive
Otter Score
β
Insufficient data
No chart data available for NAMS.
Trading Snapshot
- Day Range
- $18.29 β $19.75
- 52-Week Range
- $17.90 β $42.21
- Volume (shares)
- 170,188
- Avg Volume (shares)
- β
- Shares Outstanding
- 119.5M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $19M
- P/E Ratio
- β
- P/S Ratio
- 85.1x
- EPS (TTM)
- $-1.68
- Dividend Yield
- β
- Dilution (1yr)
- +17.9%
NEWAMSTERDAM PHARMA CO NV
NAMSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$23MβΌ β50.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.7%βΌ β0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$226Mβ² +28.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$148MβΌ β7.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
114.4Mβ² +17.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$490MβΌ β$281M YoY
About NEWAMSTERDAM PHARMA CO NV
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerβs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.